In order to assess the mechanisms of proopiomelanocortin (POMC) gene expression in human ACTH-producing tumors, we performed the simultaneous evaluation of POMC products and messenger RNA (mRNA) in tissue fragments obtained from two corticotropic adenomas, five nonpituitary tumors, and two normal human pituitaries. The POMC products were examined using a combination of gel exclusion chromatography and four different radioimmunoassays directed against "3 melanocyte stimulating hormone (y3MSH), ACTH, 'y-lipotropin ('yLPH), and f-endorphin. The POMCmRNA was detected and analyzed by dot and northern blot hybridization using a single-stranded genomic DNA probe corresponding to the coding region of the human POMC gene. Tissue concentrations of POMC products and mRNA showed parallel distributions. Immunoreactive It is concluded that POMC gene expression appears qualitatively unaltered in corticotropic adenomas. In nonpituitary tumors, in contrast, abnormal POMC processing is frequent; in addition, an extra POMCmRNA was detected in a thymic tumor with a greater length than the normal mRNA; the mechanisms and pathophysiological implications of these modifications remain to be elucidated.
Introduction mechanisms for ACTH overproduction are unknown in both circumstances.
In recent years, however, considerable progress has been made on the molecular aspects of ACTH biosynthesis. The long suspected existence of a high molecular weight ACTH-precursor molecule (4, 5) was demonstrated by the biosynthetic studies performed on the ACTH-producing AtT-20/D 16-V mouse tumor cell line (6) . Recombinant DNA methods eventually led to the complete characterization of this precursor called proopiomelanocortin (POMC)1 in many species (7) (8) (9) (10) (11) , including man (12) (13) (14) . The coordinate proteolysis of POMC, or processing, generates various peptide fragments: 16-kD fragment (16K), ACTH, f3-lipotropin (f#LPH), and a small but definite amount of (3-endorphin (,3end) and y-lipotropin (yLPH) are formed in the anterior lobe of the pituitary (15) (16) (17) . In the intermediate lobe, POMC processing goes further and smaller peptides are released, such as f3-melanocyte-stimulating hormone (,3MSH), corticotropin-like intermediate-lobe peptide (CLIP), and aMSH (18, 19) . The concept that POMC products may vary in different tissues also applies to man: several studies have shown that POMC-derived peptides are different in ACTH-producing pituitary and nonpituitary tumors (20) (21) (22) (23) (24) . Because a single functional gene has been detected for rat, beef, and human POMC (25) , it has generally been assumed that variable POMC products result from a different processing ofthe same precursor molecule in different tissues. However, variable expression ofa single gene through an alternate mode of RNA splicing has recently been recognized as a new cause of peptide heterogeneity within, for example, the products of the growth hormone and calcitonin genes (26, 27) . In the case of POMC itself, various forms of mRNAs have been detected in the rat (28, 29) and beef (30) normal tissues, some of them resulting from an alternate mode of intron removal during RNA splicing (31) .
Few data have been obtained so far with human ACTHproducing tissues. Two cases have been reported separately where a larger POMCmRNA species was detected in an ACTH-producing nonpituitary tumor (32, 33) . A similar finding was also shown in metastases of medullary thyroid carcinomas (34) . No studies have been performed with corticotropic adenomas, and no attempt was made to evaluate the final products of POMC in relation to its mRNA. We have studied the mechanisms of POMC gene expression in ACTH-producing tissues in man simultaneously at the pretranslational (POMCmRNA) and posttranslational (POMC products) levels. POMC processing was studied by analyzing its various fragments. POMCmRNA was specifically detected by northern blot analysis in the same tissues, using a genomic DNA. probe corresponding to the coding region of the human POMC gene. The data obtained in nonpituitary tumors were compared with the data obtained in normal human pituitaries and corticotropic adenomas.
Methods
Tissue collection. Nonpituitary tumors were obtained at surgery in five patients with the ectopic ACTH syndrome. El to E4 were bronchial carcinoid tumors; E5 was a thymic carcinoid tumor. Fragments of pituitary adenomas from two patients with Nelson's syndrome (N1, N2) were obtained at surgery by the transsphenoidal approach. In all cases, macroscopically homogeneous tumor fragments with no evidence of local necrosis were quickly selected by the surgeon, immediately frozen in liquid nitrogen, and subsequently stored at -850C. Two normal human pituitaries (PI, P2) were obtained at autopsy 2 and 6 h postmortem in patients with no evidence of endocrine disease and no history of prior hormonal treatment. They were frozen and stored as indicated. Patients with ACTH-producing tumors had not been subjected to either radiotherapy or chemotherapy.
Tissue extraction. For peptide studies, tissue fragments were homogenized in ice-cold 5 N acetic acid (10 ml/g tissue) containing I mM phenylmethylsulfonide fluoride (PMSF), by three to five 15-s bursts in a PCU2 Polytron (Polytron Corp., Elkhart, IN). The homogenates were centrifuged at 5,000 g for 30 min at 40C, and the supernatants were lyophilized in multiple aliquots that were subsequently used for radioimmunoassay (RIA) and/or chromatographic studies.
RIAs. Four different RIAs scanning the entire POMC molecule were used.
The y3MSH RIA was performed as described (24) using antibody 3344. Synthetic bovine -y3MSH (kindly provided by N. Ling, Salk Institute, La Jolla, CA) was used as both tracer and standard. Purified human (h)16K (kindly provided by P. J. Lowry, St. Bartholomew's Hospital, London, England) showed 24.7% cross-reactivity on a molar basis.
No significant cross-reactivity was observed with highly purified h,3LPH, hyLPH (kindly provided by D. N. Orth, Vanderbilt University, Nashville, TN), synthetic hACTH, h3MSH, aMSH (Ciba-Geigy Corp., Summit, NJ), hBend (Beckman Instruments, Fullerton, CA), and hCLIP (Peninsula Laboratories, Inc., Belmont, CA).
The ACTH RIA was performed using the COOH-terminal antibody Kathy provided by B. Eipper and R. Mains (Johns Hopkins Hospital, Baltimore, MD). Synthetic hCLIP was used as both standard and tracer, hACTH showed 100% cross-reactivity. No significant cross-reactivity was observed with ly3MSH, h 16K, aMSH, h#LPH, hBMSH, or hfend.
The hyLPH RIA was performed as described (22) using antiserum R 1547 directed against the COOH-terminal end ofthe molecule. Purified h-yLPH was used as both standard and tracer. Synthetic hBMSH showed 100% cross-reactivity. No significant cross-reactivity was observed with y3MSH, hl6K, hBLPH, hBend, or hCLIP.
The hBend RIA was performed as described (35) (37), slightly modified in our laboratory (38) . Briefly, frozen tissues were ground in liquid nitrogen, then homogenized at 4VC in a Waring blender in 20 volumes (wt/vol) of prechilled 0.02 M sodium acetate buffer, pH 5, containing 7 M guanidine-HCl. Nucleic acids were precipitated at -20'C with ethanol. DNA was removed by three washes in 3 M sodium acetate buffer, pH 5, containing 0.5% lauroyl sarcosine. After centrifugation (10 min, at -10QC) the pellet was washed twice with 80% ethanol, dried, and resuspended in sterile water. Total cellular RNA yields were in the range of 0.5-1.5 mg/g wet wt tissue.
Single-strand DNA probe. A 2.2-kb EcoRl restriction fragment containing the entire third exon of the human POMC gene and cloned into pBR 325 was kindly provided by J. Shine (13) . A smaller 657-bp Sma1-Sal, restriction fragment was subcloned into phage MI3mplO (39); this fragment is limited to the third exon and corresponds to most of the coding region for POMC, sparing the first 6 NH2-terminal amino acids and overpassing the COOH-terminal end of 35 nucleotides in the 3' noncoding region.
Preparation of the POMC DNA probe was based on the same principle as Ml 3 chain termination sequencing method. 1 pmol of the 17-mers M13 sequencing primer (40) Northern blot analysis. Extracted RNA (0. 1-20-,gg aliquots) was denatured at room temperature for 10 min in 5 mM Na2B4O7, 0.01 M Na2SO4, I mM EDTA, 0.05 M H3BO3, 0.01 M CH3HgOH (41) . Samples were loaded on a 2% agarose gel containing 0.01 M CH3HgOH and electrophoresis was performed at 100 mA for 4 h using the same buffer without CH3HgOH. Transfer to Gene Screen plus sheets was carried out according to Thomas (42) and modified in our laboratory (43) and RNA was fixed onto the membrane by air drying.
Hybridization and prehybridization were carried out in the same buffer: 3 X SSC, 10% dextran sulfate, 1% SDS, 1% glycine, 0.1% polyvinylpirolidone, 0.1% Ficoll, 100 uLg/ml of denatured sheared salmon 
Results
The tumor contents in POMC products were first estimated by direct RIA of the tissue extracts. In order to scan the entire POMC molecule, three different RIAs were used: (a) The Y3MSH
RIA-detected peptides related to the NH2-terminal end of POMC (N-POMC). Because hl6K was only 24.7% cross-reactivity, the actual molar concentration of N-POMC peptides had to be corrected by this factor once the h 1 6K/Y3MSH ratio had been determined on G-50 gel filtration. (b) The ACTH RIAdetected peptides related to the midportion of POMC (mid-POMC). (c) The hflend RIA-detected peptides related to the COOH-terminal end of POMC (C-POMC).
As shown in Simple dot blot hybridization (Fig. 4 ) of total RNA with the POMC probe detected the presence of POMCmRNA in all tissues and allowed its quantification using a normal pituitary (P2) We first examined POMC products looking for an abnormality at the posttranslational level. Four different RIAs were used in order to scan the entire POMC molecule. Concentrations of the same order of magnitude for N-, mid-, and C-POMC peptides were always found in the same tissue. Furthermore, since mid-POMC peptides were measured by an antibody that requires a free COOH-terminal end ofthe ACTH molecule, these data altogether suggested that in all our cases the POMC molecule had indeed been processed to generate its various fragments. The peculiar situation where a nonpituitary tumor may produce POMC without processing it (21) was not encountered here; this was expected, since all these patients had the clinical and biological features of Cushing's syndrome, which implies that biologically active ACTH was indeed secreted, and that POMC had thus been processed. For the same reason, the degradation of ACTH into aMSH and CLIP, which occurs in some normal and tumoral tissues (44, 45) , was similarly unexpected in our cases. Our strategy, therefore, was to examine more precisely the exact nature of the other POMC products.
We primarily focused our study on the 16K and hyLPH regions of the POMC molecule, since both peptides (h 16K and hyLPH) are thought to be terminal products of the precursor in the normal human pituitary (15, 17) . This was actually confirmed by the results observed in P1 and P2 (Figs. 1 and 2) . Similarly, we did find the same final products in the two corticotropic adenomas (N. and N2). In contrast, evidence of an abnormal POMC processing was observed in the nonpituitary tumors: although h 16K and hyLPH were present, smaller peptides with 'Y3MSH-and ,BMSH-like characteristics were also detected, indicating an exaggerated POMC processing. That these smaller peptides had been generated by nonspecific degradation during the extraction procedure appears highly unlikely for the following reasons. (a) Tissue extraction was performed in 5 N acetic acid containing PMSF as a serine protease inhibitor in order to prevent proteolysis at sites ofbasic amino acids, assuming that processing enzymes act at this level, through a trypsin-like effect. Actually, an enzyme acting specifically at pairs of basic amino acids has recently been characterized and purified in the yeast Saccharomyces cerevisiae and showed to be fully inhibited by E4 E5 20 20 PMSF (46) (48) . Cloning the Sma,-Sal, fragment in M13mplO also allowed the production of a single-stranded DNA probe (14) . Finally, an abnormal site of transcription initiation remains possible: a 250-b difference would imply that it starts upstream from the (supposed) normal promoter region. Supporting this hypothesis, analysis of the 5' flanking region reveals the following sequences: CAAACAAT (-439 to -432) and ATATTTA (-396 to -390), which could be used as an alternate promoter to initiate the transcription of the larger POMCmRNA (14) .
In conclusion, these data suggest that different pathophysiological mechanisms are responsible for ACTH overproduction in pituitary and nonpituitary tumors. In the pituitary corticotropic adenoma the overall phenomenon of POMC gene expression appears qualitatively unmodified, the mRNA and peptide products all being indistinguishable from normal. The alteration, therefore, seems quantitative, pointing to a possible abnormality in the mechanisms that normally regulate the rate of POMC gene transcription. In nonpituitary tumors, in contrast, abnormal POMC processing is a frequent phenomenon which occurs in the presence of a normal POMCmRNA in most cases. The generation of an altered POMCmRNA, although probably a rare event, has been demonstrated in a thymic tumor. The exact nature and the pathophysiological implications of this larger mRNA species remain to be elucidated.
These results on hPOMC tumor expression may provide a more general model for the study ofectopic hormone production and altered posttranslational processing.
